scholarly journals Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study

2021 ◽  
Vol Volume 13 ◽  
pp. 267-274
Author(s):  
Alan Morrison ◽  
Melissa E Stauffer ◽  
Anna S Kaufman
2009 ◽  
Vol 154 (S312) ◽  
pp. 425-428
Author(s):  
Karl-Erik Fjellström ◽  
Leonard Goldberg ◽  
Gunnar Lindgren ◽  
Fried Nilsson

2016 ◽  
Vol 78 (6-8) ◽  
Author(s):  
Nemtsev Alexey ◽  
Smirnov Ivan ◽  
Murashko Tatyana ◽  
Ivanov Alexey ◽  
Bondarev Alex ◽  
...  

Rheumatoid arthritis (RA) is a chronic inflammatory multifactorial disorder affecting approximately 1% of population, with over 3000000 new cases annually. The principal pharmacological agents are nonsteroidal anti-inflammatory drugs (NSAID). Patients with rheumatoid arthritis are vulnerable to NSAID-associated gastrointestinal complications. Based on these findings we developed a new NSAID agent based on phenolic glycoside structure methyl (4-О-β-glucopyranosyloxy)-benzoic acid. In this study we evaluated the methyl (4-О-β-glucopyranosyloxy)-benzoic acid therapeutic effect in adjuvant-induced rat arthritis compared to etoricoxib effect. According to the results, methyl (4-О-β-glucopyranosyloxy)-benzoic acid activity was superior to etoricoxib, paw volume returned to the initial value 2 days early, than it did in etoricoxib group. Therefore, methyl (4-О-β-glucopyranosyloxy)-benzoic acid might contest to the modern antirheumatic drug etoricoxib. 


Theranostics ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. 708-720 ◽  
Author(s):  
Yunlong Wang ◽  
Zhongbing Liu ◽  
Ting Li ◽  
Lin Chen ◽  
Jiayao Lyu ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Meng Zhang ◽  
Hongwei Ren ◽  
Kun Li ◽  
Shengsheng Xie ◽  
Ru Zhang ◽  
...  

Abstract Background Rheumatoid arthritis (RA) is an autoimmune disease which causes disability and threatens the health of humans. Therefore, it is of great significance to seek novel effective drugs for RA. It has been reported that various ginsenoside monomers are able to treat RA. However, it is still unclear which ginsenoside is the most effective and has the potential to be developed into an anti-RA drug. Methods The ginsenosides, including Rg1, Rg3, Rg5, Rb1, Rh2 and CK, were evaluated and compared for their therapeutic effect on RA. In in vitro cell studies, methotrexate (MTX) and 0.05% dimethyl sulfoxide (DMSO) was set as a positive control group and a negative control group, respectively. LPS-induced RAW264.7 cells and TNF-α-induced HUVEC cells were cultured with MTX, DMSO and six ginsenosides, respectively. Cell proliferation was analyzed by MTT assay and cell apoptosis was carried out by flow cytometry. CIA mice model was developed to evaluate the therapeutic efficacy of ginsenosides. The analysis of histology, immunohistochemistry, flow cytometry and cytokine detections of the joint tissues were performed to elucidate the action mechanisms of ginsenosides. Results All six ginsenosides showed good therapeutic effect on acute arthritis compared with the negative control group, Ginsenoside CK provided the most effective treatment ability. It could significantly inhibit the proliferation and promote the apoptosis of RAW 264.7 and HUVEC cells, and substantially reduce the swelling, redness, functional impairment of joints and the pathological changes of CIA mice. Meanwhile, CK could increase CD8 + T cell to down-regulate the immune response, decrease the number of activated CD4 + T cell and proinflammatory M1-macrophages, thus resulting in the inhibition of the secretion of proinflammatory cytokine such as TNF-α and IL-6. Conclusion Ginsenoside CK was proved to be a most potential candidate among the tested ginsenosides for the treatment of RA, with a strong anti-inflammation and immune modulating capabilities.


Sign in / Sign up

Export Citation Format

Share Document